DZIP1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by disruption of the DZIP1 gene in HeLa cells. This product provides a mixed population of knockout cells for studying loss-of-function effects without clonal selection, suitable for assays requiring a heterogeneous background.
HeLa cells are an immortalized human cervical epithelial adenocarcinoma cell line originally derived from a 31-year-old Black female patient. Widely used in biomedical research, HeLa cells serve as a model system for studying cell cycle regulation, apoptosis, and gene expression. Their robust growth and well-characterized signaling networks make them an ideal host for targeted gene disruption studies.
DZIP1 encodes a centrosomal protein critical for primary cilium assembly and Hedgehog signaling. It functions in ciliary trafficking, facilitating the processing of GLI transcription factors (GLI1, GLI2, GLI3) downstream of Hedgehog ligands (SHH, IHH, DHH). DZIP1 interacts with ciliary transport proteins such as IFT88 and BBS4, and its activity modulates the expression of target genes including PTCH1, CCND1, and MYCN. Disruption of DZIP1 thus impairs the Hedgehog pathway transduction from receptor activation to transcriptional response.
In HeLa cells, loss of DZIP1 disrupts primary cilium-dependent Hedgehog signaling, leading to attenuated GLI transcriptional activity and altered expression of cell cycle regulators. This model is particularly relevant for studying the role of centrosomal proteins in cancer progression, as aberrant Hedgehog signaling is implicated in cervical adenocarcinoma and other malignancies. The polyclonal knockout population approximates a heterogeneous tumor environment, enabling robust functional studies.
This knockout product is applicable to diverse research areas, including investigation of ciliopathies, Hedgehog-driven oncogenesis, and centrosomal protein function. Standard assays such as Western blot for GLI1, RT-qPCR for PTCH1 and CCND1, immunofluorescence for ciliary markers (Arl13b, acetylated tubulin), Gli-responsive luciferase reporter assays, and flow cytometry for cell cycle analysis can be employed. Additionally, migration and invasion assays enable assessment of metastatic potential. For detailed product information or technical support, please contact Ascent Research.
